[HTML][HTML] Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: exploratory analysis from the …
OBJECTIVE These post hoc analyses of the Semaglutide Treatment Effect in People with
obesity (STEP) 1–3 trials (NCT03548935, NCT03552757, and NCT03611582) explored the …
obesity (STEP) 1–3 trials (NCT03548935, NCT03552757, and NCT03611582) explored the …
Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes
V Perkovic, KR Tuttle, P Rossing… - … England Journal of …, 2024 - Mass Medical Soc
Background Patients with type 2 diabetes and chronic kidney disease are at high risk for
kidney failure, cardiovascular events, and death. Whether treatment with semaglutide would …
kidney failure, cardiovascular events, and death. Whether treatment with semaglutide would …
Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised …
Background Patients with type 2 diabetes have a high risk of developing chronic kidney
disease. We examined the effects of semaglutide on kidney function and safety in a large …
disease. We examined the effects of semaglutide on kidney function and safety in a large …
Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression—real-world clinical practice
B Aviles Bueno, MJ Soler… - Clinical Kidney …, 2022 - academic.oup.com
Background Semaglutide [glucagon-like peptide-1 receptor-agonist (GLP-1RA)] has shown
nephroprotective effects in previous cardiovascular studies. However, its efficacy and safety …
nephroprotective effects in previous cardiovascular studies. However, its efficacy and safety …
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
O Mosenzon, TM Blicher, S Rosenlund… - The lancet Diabetes & …, 2019 - thelancet.com
Background Oral semaglutide is the first oral glucagon-like peptide-1 (GLP-1) receptor
agonist for glycaemic control in patients with type 2 diabetes. Type 2 diabetes is commonly …
agonist for glycaemic control in patients with type 2 diabetes. Type 2 diabetes is commonly …
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
Background Chronic kidney disease (CKD) is a common complication of type 2 diabetes
(T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control …
(T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control …
[HTML][HTML] Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide …
KR Tuttle, H Bosch-Traberg, DZI Cherney, S Hadjadj… - Kidney international, 2023 - Elsevier
Glucagon-like peptide-1 receptor agonists reduce albuminuria and may stabilize the
estimated glomerular filtration rate (eGFR) in people with type 2 diabetes (T2D). In this post …
estimated glomerular filtration rate (eGFR) in people with type 2 diabetes (T2D). In this post …
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular …
P Rossing, SC Bain, H Bosch-Traberg… - Cardiovascular …, 2023 - Springer
Background Semaglutide is a glucose-lowering treatment for type 2 diabetes (T2D) with
demonstrated cardiovascular benefits; semaglutide may also have kidney-protective effects …
demonstrated cardiovascular benefits; semaglutide may also have kidney-protective effects …
Effect of semaglutide on regression and progression of glycemia in people with overweight or obesity but without diabetes in the SELECT trial
SE Kahn, JE Deanfield, OK Jeppesen… - Diabetes …, 2024 - diabetesjournals.org
OBJECTIVE To determine whether semaglutide slows progression of glycemia in people
with cardiovascular disease and overweight or obesity but without diabetes. RESEARCH …
with cardiovascular disease and overweight or obesity but without diabetes. RESEARCH …
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses
MN Kosiborod, M Bhatta, M Davies… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aims Evaluate the effects of once‐weekly subcutaneous semaglutide 2.4 mg on
cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP …
cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP …